病例报告: 在ozanimod的无症状斑点
Valentina Annamaria Mauceri1, Tommaso Torresin1,2, Elisa Basili1,3
1Department of Neurosciences, University of Padua, Padua, Italy.
Frontiers in ophthalmology
|October 23, 2025
概括
奥扎尼莫德是一种基-1-酸盐受体 (S1PR) 调节剂,可在多发性硬化症 (MS) 患者中引起无症状黄斑胀 (ME). 定期的眼睛监测至关重要,特别是对于那些以前有视网膜疾病的人来说,以早期发现这种罕见的不良事件.
科学领域:
- 眼科医生 眼科 眼科
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性复发性多发性硬化症 (RRMS) 管理包括免疫调节疗法.
- 像ozanimod一样的sphingosine-1-phosphate受体 (S1PR) 调制剂用于MS治疗.
- 眼部不良事件,包括黄斑 (ME),是S1PR调节器的潜在副作用.
研究的目的:
- 在RRMS患者中报告无症状黄斑 (ME) 的病例,该患者接受了ozanimod.mod治疗.
- 强调在S1PR调节器治疗期间眼科监测的重要性.
- 讨论S1PR调节器与ME发展之间的潜在联系.
主要方法:
- 一个61岁的RRMS患者的病例报告.
- 眼科检查和光学连贯性断层扫描 (OCT) 用于监测.
- 停止使用ozanimod并对ME的后续评估.
主要成果:
- 患者在开始ozanimod.com的三个月后在左眼部出现无症状斑点 (ME).
- 经过OCT检测出ME,尽管没有视觉症状.
- 在停止使用ozanimod后的两个月内,ME逐渐消失.
结论:
- 在ozanimod治疗期间,眼科监测对于早期检测无症状ME至关重要.
- 以前的视网膜病理可能会增加S1PR调节器患者ME的风险.
- 跨学科管理和OCT是管理S1PR调节器治疗的MS患者眼部不良事件的有价值的工具.
更多相关视频
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
4.1K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.5K
相关概念视频
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:26Nephrotic Syndrome II : Assessment and Medical Management
422
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
422
01:22Cerebral Edema ll: Pathophysiology
31
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
31
01:21Cytotoxic Edema: Pathophysiology
31
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous...
31